Notice

As a result of the current Federal government funding situation, the information on this website may not be up to date or acted upon.  

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at https://www.opm.gov/.

Antibody Characterization Process

The goal of the NCI's Antibody Characterization Program (ACP) is to have three monoclonal antibodies produced for each successfully expressed/purified recombinant antigen and one antibody per peptide (1 to 3 peptides per protein). To date, over 4000 clones have been screened before selecting the current 393 antibodies. They are winnowed down based on the projected end use of the antibody. The ACP selects up to three monoclonal antibodies that are further extensively characterized by ELISA, Western Blot, IHC, SPR, and Nucleic Acid Programmable Protein Array (NAPPA) (see pipeline) and made available to the scientific community.

CPTC Characterized Antibody

 

CPTC Characterized Antibody

CPTC Characterized AntibodyThe text and trademark CPTC Characterized Antibody denotes the antibodies listed on the Antibody Portal. These antibodies with the term “CPTC” have been characterized through a standardized process (see above) and the data from this analysis is publicly available through the National Cancer Institute. "CPTC" stands for Clinical Proteomic Technologies for Cancer Initiative.